Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticaria (CSU) drug into phase 2, instead preparing to sell the asset while liquidating the business.
All entries for: Third Harmonic Bio
May 8, 2025
Third Harmonic Bio
Company Closure
San Francisco, CA
1-50 employees
Disease Area: Gastrointestinal, Immune Diseases, Multiple, Respiratory Diseases
Drug Type: Small Molecule